Last reviewed · How we verify
NCT02333565: CEVOREM
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
Completed
Phase 2
Last updated 25 May 2023
What this trial tests
Phase 2 trial testing Everolimus in Recurrent Meningiomas in 20 participants. Completed in 24 May 2023.
Timeline
22 January 2015
Primary endpoint
21 January 2019
21 January 2019
24 May 2023
Quick facts
| Lead sponsor | Assistance Publique Hopitaux De Marseille |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 22 January 2015 |
| Primary completion | 21 January 2019 |
| Estimated completion | 24 May 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Everolimus (everolimus) — full drug profile →
- Octreotide (OCTREOTIDE) — full drug profile →
Conditions studied
- Recurrent Meningiomas — all drugs for Recurrent Meningiomas →
- Resistant Meningiomas — all drugs for Resistant Meningiomas →
Sponsor
Assistance Publique Hopitaux De Marseille — full company profile →
Who can join
18 and older, any sex, with Recurrent Meningiomas or Resistant Meningiomas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine if combination of everolimus and octreotide exert an anti-tumoral activity in recurrent and/or aggressive meningiomas growth with limited adverse effects.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
An overview of meningiomas.
Buerki RA, Horbinski CM, Kruser T, Horowitz PM, et al · · 2018 · cited 325× · PMID 30084265 · DOI 10.2217/fon-2018-0006 -
Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions.
Ogasawara C, Philbrick BD, Adamson DC. · · 2021 · cited 183× · PMID 33801089 · DOI 10.3390/biomedicines9030319 -
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.
Wang JZ, Landry AP, Raleigh DR, Sahm F, et al · · 2024 · cited 100× · PMID 38695575 · DOI 10.1093/neuonc/noae082 -
Meningioma: A Review of Clinicopathological and Molecular Aspects.
Huntoon K, Toland AMS, Dahiya S. · · 2020 · cited 96× · PMID 33194703 · DOI 10.3389/fonc.2020.579599 -
Recent Advances in Meningioma Immunogenetics.
Al-Rashed M, Foshay K, Abedalthagafi M. · · 2019 · cited 39× · PMID 31970090 · DOI 10.3389/fonc.2019.01472 -
Emerging Medical Treatments for Meningioma in the Molecular Era.
Nigim F, Wakimoto H, Kasper EM, Ackermans L, et al · · 2018 · cited 29× · PMID 30082628 · DOI 10.3390/biomedicines6030086 -
Recent advances in managing/understanding meningioma.
Shaikh N, Dixit K, Raizer J. · · 2018 · cited 24× · PMID 29770198 · DOI 10.12688/f1000research.13674.1 -
Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas.
Pemov A, Dewan R, Hansen NF, Chandrasekharappa SC, et al · · 2020 · cited 22× · PMID 32724039 · DOI 10.1038/s41598-020-69074-z
Verify or expand the search:
- PubMed search for NCT02333565
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Everolimus
Trials testing the same drug.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07318324 — Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer · Phase 1 · not yet recruiting
- NCT07477548 — A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies · Phase 2 · not yet recruiting
- NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
- NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting
Other Assistance Publique Hopitaux De Marseille trials
Trials by the same sponsor.
- NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
- NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
- NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
- NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
- NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02333565 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
- Last refreshed: 25 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02333565.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing